Modality
Gene Therapy
MOA
TNFi
Target
CD47
Pathway
JAK/STAT
BCCFSGSEndometrial Ca
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
Apr 2019
→ Mar 2028
Phase 2Current
NCT06794103
670 pts·Endometrial Ca
2020-04→2025-07·Terminated
NCT08999375
19 pts·BCC
2019-04→2028-03·Terminated
689 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-129mo agoPh2 Data· Endometrial Ca
2028-03-252.0y awayPh2 Data· BCC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Termina…
P2
Termina…
Catalysts
Ph2 Data
2025-07-12 · 9mo ago
Endometrial Ca
Ph2 Data
2028-03-25 · 2.0y away
BCC
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06794103 | Phase 2 | Endometrial Ca | Terminated | 670 | PASI75 |
| NCT08999375 | Phase 2 | BCC | Terminated | 19 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |